Arteris, Inc. (AIP) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-28

Key Insights

Director Viana Antonio J sold 20,000 shares on 04/24/2026 at a weighted average price of $26.11, representing a substantial equity reduction executed through a Rule 10b5-1 trading plan adopted in June 2025.
The sale was conducted via a pre-planned trading arrangement, indicating this was a scheduled divestment rather than a reactive market decision, which reduces concerns about negative company-specific catalysts.
Post-transaction, the reporting person retains 145,460 shares of beneficial ownership (124,620 indirect through Viana Family Trust and 20,840 direct), demonstrating continued material stake in the company despite the sale.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-28

Director Chitkara Raman sold 5,000 shares on 04/24/2026 at a weighted average price of $25.06, reducing beneficial ownership from 152,867 to 147,867 shares, representing a modest 3.3% reduction in position.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 7, 2025, indicating pre-planned, systematic selling rather than opportunistic or distressed selling, which reduces negative signal strength.
Shares were sold across a narrow price range ($25.00-$25.25), suggesting stable stock performance during the transaction period and no apparent attempt to time market weakness.
The director retained substantial beneficial ownership of 147,867 shares after the sale, demonstrating continued confidence in the company despite the divestment activity.

Filed: 2026-04-21

Director Viana Antonio J sold 20,000 shares on 04/17/2026 at a weighted average price of $22.11, representing a material insider sale executed under a Rule 10b5-1 trading plan adopted in June 2025.
The sale was conducted under a pre-arranged trading plan, indicating this was a planned transaction rather than a reactive market decision, which reduces the significance as a negative signal about company prospects.
Post-transaction, the reporting person maintains significant beneficial ownership of 144,620 shares indirectly through the Viana Family Trust plus 20,840 shares directly, demonstrating continued substantial stake in the company despite the sale.

Filed: 2026-04-21

Director Raza Saiyed executed two significant stock sales totaling 89,999 shares (~$2M in proceeds) on April 17-20, 2026 at prices between $22.00-$22.46, representing a material reduction in direct holdings from approximately 109,838 shares to 20,839 shares.
Sales were executed under a pre-established Rule 10b5-1 trading plan adopted on November 7, 2025, indicating these were pre-planned transactions rather than reactive market timing, which reduces insider trading concerns but suggests confidence in current valuation.
Indirect holdings through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust remain substantial at 300,000 shares post-transaction, indicating the insider maintained significant beneficial ownership despite the direct share reduction.

Filed: 2026-04-16

The reporting person, Laurent R. Moll, the Chief Operating Officer of Arteris, Inc., sold 13,448 shares of the company's common stock on April 14, 2026 pursuant to a 10b5-1 trading plan.
The sale price of the shares ranged from $19.90 to $20.22 per share, resulting in a weighted average sale price of $20.0313 per share.
Following the reported transaction, the reporting person still beneficially owns 265,530 shares of Arteris, Inc. common stock.

Filed: 2026-04-16

Chitkara Raman, a director at Arteris, Inc. (AIP), sold 5,000 shares of common stock on April 14, 2026 at a weighted average price of $20.0508 per share.
Following the reported transaction, Chitkara Raman's direct beneficial ownership in Arteris decreased to 152,867 shares.
The sale of shares by a director may indicate reduced confidence in the company's near-term prospects or a personal need for liquidity.

Filed: 2026-04-14

Laurent R. Moll, the Chief Operating Officer of Arteris, Inc., sold a total of 1,993 shares of the company's common stock on April 10 and April 13, 2026.
The sales were made pursuant to a 10b5-1 trading plan that Moll adopted on March 12, 2025, indicating prearranged transactions.
Following the reported transactions, Moll still beneficially owns 278,979 shares of Arteris common stock, suggesting he continues to maintain a significant equity stake in the company.

Filed: 2026-04-09

Bayview Legacy, LLC, which is controlled by K. Charles Janac, sold 70,000 shares of Arteris, Inc. (AIP) stock on April 8, 2026 at an average price of $19.0398.
The sale was made pursuant to a 10b5-1 trading plan that was adopted by K. Charles Janac on March 5, 2025, indicating a pre-planned transaction.
After the sale, Bayview Legacy, LLC still holds a significant position of 9,119,071 shares, suggesting they remain bullish on the company's long-term prospects.

Filed: 2026-04-09

K. Charles Janac, the President and CEO of Arteris, Inc., made a significant sale of 70,000 shares of the company's common stock on April 8, 2026, representing a substantial portion of his direct holdings.
Janac's indirect beneficial ownership through Bayview Legacy, LLC and the Charles and Lydia Janac Trust remains substantial, indicating he continues to hold a significant stake in the company.
The sale was executed pursuant to a 10b5-1 trading plan, suggesting the transaction was planned in advance and not a reaction to immediate events.

Filed: 2026-04-07

Joachim Kunkel, a director of Arteris, Inc., acquired 899 shares of common stock through a grant of fully vested restricted stock, increasing his direct beneficial ownership to 69,627 shares.
The restricted stock grant represents Kunkel's election to receive his director retainer fees in the form of equity rather than cash, aligning his interests with shareholders.
The timing and amount of this insider purchase suggest continued confidence in Arteris' prospects and a long-term commitment to the company by a key board member.

Filed: 2026-04-07

Claudia F. Munce, a director of Arteris, Inc. (AIP), acquired 860 shares of the company's common stock on April 5, 2026 at no cost, likely as part of director compensation.
Munce's total direct ownership in Arteris increased to 101,711 shares following this transaction, indicating her continued commitment to the company.
The Form 4 filing suggests Munce elected to defer the receipt of these shares, potentially signaling her confidence in Arteris' long-term prospects.

Filed: 2026-04-06

Nicholas B. Hawkins, the VP and Chief Financial Officer of Arteris, Inc. (AIP), sold a total of 4,870 shares of common stock on April 2, 2026 to satisfy his tax liability arising from the release of restricted stock units.
The shares were sold at an average price of $17.6528, indicating a total transaction value of approximately $86,000.
This transaction appears to be a routine sell-to-cover event, as the filing notes that the sales were mandated by the company's equity incentive plans and did not represent discretionary trades by the reporting person.

Filed: 2026-04-06

The reporting person, Paul Alpern, who is the VP and General Counsel of Arteris, Inc. (AIP), has sold a total of 3,649 shares of the company's common stock on April 2, 2026 to satisfy his tax liability arising from the release of restricted stock units.
The sales were mandatory 'sell to cover' transactions to fund the tax withholding obligations, and do not represent discretionary trades by the reporting person.
After the reported transactions, the reporting person still holds 86,386 shares of Arteris' common stock, indicating he continues to maintain a significant ownership stake in the company.

Filed: 2026-04-06

Key insider, Charles Janac, sold over 19,000 shares of Arteris, Inc. (AIP) stock on April 2 and April 6, 2026, reducing his direct holdings by 9%.
The sales appear to be primarily for tax purposes, as they were executed under a 10b5-1 trading plan to cover tax withholding obligations on the release of restricted stock units.
Despite the insider selling, Janac remains a significant shareholder, holding over 9.2 million shares indirectly through Bayview Legacy, LLC and 56,252 shares through a personal trust.

Filed: 2026-04-06

The reporting person, Laurent R. Moll, who is the Chief Operating Officer of Arteris, Inc., has sold a total of 5,202 shares of the company's common stock over the past few days.
The sales were made to satisfy the reporting person's tax liability arising from the release of restricted stock units, which was mandated by the company's equity incentive plans.
The reporting person also made a sale of 1,552 shares on April 6, 2026, pursuant to a pre-arranged 10b5-1 trading plan that was adopted on March 12, 2025.

Filed: 2026-03-27

The reporting person, K. Charles Janac, who is the President and CEO of Arteris, Inc. as well as a 10% owner, has engaged in significant insider selling of the company's common stock over the past two days, disposing of a total of 40,000 shares.
The insider selling appears to be part of a pre-planned 10b5-1 trading plan that was adopted by the reporting person in March 2025, suggesting the transactions may not be driven by near-term concerns about the company's outlook.
However, the relatively large amount of shares sold, representing around 0.4% of the company's outstanding common stock, may raise some questions from investors about the reporting person's confidence in the company's future performance.

Filed: 2026-03-27

Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), has sold a total of 40,000 shares of the company's common stock on March 25-26, 2026 at weighted average prices of $18.0309 and $18.3458 respectively.
The transactions were made pursuant to a 10b5-1 trading plan adopted by Bayview Legacy's manager, K. Charles Janac, on March 5, 2025.
K. Charles Janac, as the manager of Bayview Legacy, LLC, is deemed to have voting and dispositive power over the shares beneficially owned by the entity.

Filed: 2026-03-11

Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), sold a total of 50,000 shares of common stock over two trading days, March 9 and 10, 2026, at weighted average prices of $14.21 and $14.66 respectively.
The sale of these shares by a significant shareholder could signal a potential shift in the company's ownership structure or investor sentiment towards the stock.
Investors should monitor any further changes in Bayview Legacy, LLC's ownership position and consider the potential implications for the company's future performance and shareholder value.

Filed: 2026-01-20

Insider K. Charles Janac, the President and CEO, as well as a 10% owner, has sold 17,884 shares of Arteris, Inc. (AIP) stock. This transaction was made pursuant to a pre-established 10b5-1 trading plan.
Janac continues to hold a significant ownership stake in the company, with 9,399,071 shares indirectly owned through Bayview Legacy, LLC, which he manages, and an additional 195,739 shares held directly and through a trust.
The sale was executed at a weighted average price of $17.84 per share, generating proceeds of approximately $318,500.

Filed: 2026-01-20

Bayview Legacy, LLC, a 10% owner of Arteris Inc. (AIP), sold 17,884 shares of common stock on January 15, 2026 at a weighted average price of $17.84 per share.
The sale was made pursuant to a 10b5-1 trading plan that was adopted by Bayview Legacy, LLC on March 5, 2025.
K. Charles Janac, the manager of Bayview Legacy, LLC, has also filed a Form 4 reporting the same transaction, as he has beneficial ownership of the shares through the LLC.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.